EP1313512A4 - Facteur 2 de croissance endoth liale (vegf-2) - Google Patents

Facteur 2 de croissance endoth liale (vegf-2)

Info

Publication number
EP1313512A4
EP1313512A4 EP01963814A EP01963814A EP1313512A4 EP 1313512 A4 EP1313512 A4 EP 1313512A4 EP 01963814 A EP01963814 A EP 01963814A EP 01963814 A EP01963814 A EP 01963814A EP 1313512 A4 EP1313512 A4 EP 1313512A4
Authority
EP
European Patent Office
Prior art keywords
growth factor
vascular endothelial
endothelial growth
vascular
factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01963814A
Other languages
German (de)
English (en)
Other versions
EP1313512A1 (fr
Inventor
Timothy A Coleman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of EP1313512A1 publication Critical patent/EP1313512A1/fr
Publication of EP1313512A4 publication Critical patent/EP1313512A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Plant Pathology (AREA)
EP01963814A 2000-08-04 2001-08-03 Facteur 2 de croissance endoth liale (vegf-2) Withdrawn EP1313512A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22327600P 2000-08-04 2000-08-04
US223276P 2000-08-04
PCT/US2001/024658 WO2002011769A1 (fr) 2000-08-04 2001-08-03 Facteur 2 de croissance endothéliale (vegf-2)

Publications (2)

Publication Number Publication Date
EP1313512A1 EP1313512A1 (fr) 2003-05-28
EP1313512A4 true EP1313512A4 (fr) 2004-08-25

Family

ID=22835805

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01963814A Withdrawn EP1313512A4 (fr) 2000-08-04 2001-08-03 Facteur 2 de croissance endoth liale (vegf-2)

Country Status (10)

Country Link
US (2) US7273751B2 (fr)
EP (1) EP1313512A4 (fr)
JP (1) JP2004505619A (fr)
KR (1) KR20020059609A (fr)
CN (1) CN1211126C (fr)
AU (1) AU8473401A (fr)
CA (1) CA2386103A1 (fr)
MX (1) MXPA02003434A (fr)
NZ (1) NZ518077A (fr)
WO (1) WO2002011769A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US6040157A (en) 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
CN1267550C (zh) 1994-03-08 2006-08-02 人体基因组科学有限公司 血管内皮生长因子2
WO2002060950A2 (fr) * 1994-11-14 2002-08-08 Ludwig Institute For Cancer Research Flt4 (vegfr-3) utilise comme cible pour l'imagerie des tumeurs et le traitement antitumoral
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US20040228834A1 (en) * 1998-03-09 2004-11-18 Jeffrey Isner Compositions and methods for modulating vascularization
US7223724B1 (en) * 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
KR20020059609A (ko) * 2000-08-04 2002-07-13 벤슨 로버트 에이치. 혈관 내피 성장 인자 ２
US7611711B2 (en) * 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
DE60236646D1 (de) 2001-04-13 2010-07-22 Human Genome Sciences Inc Anti-VEGF-2 Antikörper
AU2002252631A1 (en) * 2001-04-13 2002-10-28 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US20050232921A1 (en) * 2001-04-13 2005-10-20 Rosen Craig A Vascular endothelial growth factor 2
EP1425580A4 (fr) * 2001-07-12 2006-03-29 Ludwig Inst Cancer Res Cellules endotheliales lymphatiques et procedes correspondants
US20030113324A1 (en) * 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
US20040214766A1 (en) * 2001-10-01 2004-10-28 Kari Alitalo VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
WO2004070018A2 (fr) * 2003-02-04 2004-08-19 Ludwig Institute For Cancer Research Modulation vegf-b et pdgf de cellules souches
WO2005016963A2 (fr) * 2003-06-12 2005-02-24 Ludwig Institute For Cancer Research Ligands de recepteur 3 du facteur de croissance des cellules endotheliales de liaison a l'heparine
EP1635860A2 (fr) * 2003-06-12 2006-03-22 Ludwig Institute For Cancer Research Utilisation de vegf-c ou de vegf-d en chirurgie reconstructive
CN100448892C (zh) * 2006-08-02 2009-01-07 中国人民解放军军事医学科学院基础医学研究所 抗肿瘤血管内皮生长因子受体vegf－r2抗原及其编码基因与应用
US20120141424A1 (en) * 2009-01-07 2012-06-07 Vegenics Pty Limited Materials and Methods for the Treatment of Hypertension
AU2010286511B2 (en) 2009-08-28 2016-05-26 Juventas Therapeutics, Inc. SDF-1 delivery for treating ischemic tissue
WO2011079222A2 (fr) 2009-12-23 2011-06-30 Boston Scientific Scimed, Inc. Méthode moins traumatique de pose de dispositifs à maillage dans le corps humain
WO2014124487A1 (fr) 2013-02-18 2014-08-21 Vegenics Pty Limited Molécules de liaison à des ligands et utilisations de celles-ci
US20200113972A1 (en) * 2017-04-14 2020-04-16 Rhode Island Hospital Vegf gene therapy for tendon and ligament injuries

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999046364A1 (fr) * 1998-03-13 1999-09-16 Human Genome Sciences, Inc. Facteur de croissance endothelial vasculaire 2

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0186084B1 (fr) 1984-12-24 1991-09-04 Merck & Co. Inc. Facteur de croissance dérivé du cerveau
US5073492A (en) 1987-01-09 1991-12-17 The Johns Hopkins University Synergistic composition for endothelial cell growth
JPS6438100U (fr) 1987-08-26 1989-03-07
JPH02117698A (ja) 1988-10-27 1990-05-02 Toray Ind Inc 血管内皮細胞成長因子
US5240848A (en) 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
CA2017379C (fr) 1989-05-24 2002-06-25 Kenneth A. Thomas, Jr. Purification et caracterisation d'un facteur de croissance derive de gliomes
US5219739A (en) 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
US5194596A (en) 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
DE69132040T2 (de) 1990-09-21 2000-11-02 Merck & Co Inc Wachstumsfaktor II für vaskuläre Endothelzellen
SG49753A1 (en) 1991-02-22 1998-06-15 American Cyanamid Co Identification of a novel human receptor tyrosine kinase gene
CA2064331C (fr) 1991-03-28 2003-02-18 Marvin L. Bayne Sous-unite c du facteur de croissance des cellules endotheliales des vaisseaux
US5185438A (en) 1991-04-02 1993-02-09 The Trustees Of Princeton University Nucleic acids encoding hencatoporetic stem cell receptor flk-2
US5234908A (en) 1991-04-12 1993-08-10 Creative Biomolecules, Inc. Method of treating gastrointestinal ulcers with platelet derived growth factor
US5661133B1 (en) 1991-11-12 1999-06-01 Univ Michigan Collateral blood vessel formation in cardiac muscle by injecting a dna sequence encoding an angiogenic protein
US5861301A (en) 1992-02-20 1999-01-19 American Cayanamid Company Recombinant kinase insert domain containing receptor and gene encoding same
US5326695A (en) 1992-05-15 1994-07-05 Ludwig Institute For Cancer Research Platelet derived growth factor agonists
US5776755A (en) 1992-10-09 1998-07-07 Helsinki University Licensing, Ltd. FLT4, a receptor tyrosine kinase
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
WO1994011506A1 (fr) 1992-11-18 1994-05-26 Arch Development Corporation Transfert de genes au moyen d'un adenovirus au muscle lisse cardiaque et vasculaire
US5922572A (en) 1994-01-25 1999-07-13 Human Genome Sciences, Inc. Polynucleotides encoding haemopoietic maturation factor
CN1267550C (zh) * 1994-03-08 2006-08-02 人体基因组科学有限公司 血管内皮生长因子2
US6734285B2 (en) * 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
US5633147A (en) 1994-03-08 1997-05-27 Human Genome Sciences, Inc. Transforming growth factor αH1
US7153827B1 (en) * 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US7186688B1 (en) * 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US6040157A (en) 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US5817485A (en) 1994-03-08 1998-10-06 Human Genome Sciences, Inc. Nucleic acids and cells for recombinant production of fibroblast growth factor-10
US7109308B1 (en) * 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US5932540A (en) * 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
ATE262345T1 (de) 1994-08-23 2004-04-15 Human Genome Sciences Inc Menschliche chemokin-polypeptide
US5652225A (en) 1994-10-04 1997-07-29 St. Elizabeth's Medical Center Of Boston, Inc. Methods and products for nucleic acid delivery
US6645933B1 (en) 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
WO1998033917A1 (fr) 1994-11-14 1998-08-06 The Ludwig Institute For Cancer Research Proteine et gene du facteur de croissance vasculaire endothelial c (vegf-c), mutants de ce dernier et utilisations
US6130071A (en) 1997-02-05 2000-10-10 Helsinki University Licensing, Ltd. Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof
US6403088B1 (en) 1995-08-01 2002-06-11 Helsinki University Licensing, Ltd. Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
US6245530B1 (en) 1995-08-01 2001-06-12 Ludwig Institute For Cancer Research Receptor ligand
US6221839B1 (en) 1994-11-14 2001-04-24 Helsinki University Licensing Ltd. Oy FIt4 ligand and methods of use
US5792453A (en) 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
US5928939A (en) 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
US5607918A (en) 1995-03-01 1997-03-04 Ludwig Institute For Cancer Research Vascular endothelial growth factor-B and DNA coding therefor
EP2258726A1 (fr) 1995-06-14 2010-12-08 The Regents of the University of California Anticorps humains à haute affinité pour c-erbB-2
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
EP0848755B2 (fr) 1995-09-08 2011-02-09 Genentech, Inc. Proteine apparentee au vegf
US6121246A (en) 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
WO1997017442A1 (fr) 1995-11-08 1997-05-15 Immunex Corporation Proteine de liaison flk-1
US5641750A (en) 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
PT950100E (pt) 1996-08-13 2004-06-30 Human Genome Sciences Inc Mutantes do factor 2 de crescimento dos ceranocitos (fcc-2 ou factor 12 de crescimento dos fibroblastos fcf-12)
EP1749836B1 (fr) 1996-08-23 2009-06-17 Vegenics Limited Facteur D recombinant de croissance de cellules vasculaires endothéliales
WO1998024811A2 (fr) 1996-12-06 1998-06-11 Zymogenetics, Inc. Facteur de croissance endotheliale vasculaire
JP2001509168A (ja) 1997-01-29 2001-07-10 コーネル リサーチ ファウンデーション、インコーポレイティッド 血管新生を誘導するためのアデノウイルスベクターの多部位送達
US6486133B1 (en) 1997-03-07 2002-11-26 The Wistar Institute Of Anatomy And Biology Methods for inducing localized vascular development and enhancing the repair of a wound in the mammamian dermis
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
WO1998049300A2 (fr) 1997-04-25 1998-11-05 Collateral Therapeutics Formes tronquees de proteines apparentees au facteur vegf
EP0990034A1 (fr) 1997-06-06 2000-04-05 Asat AG Applied Science & Technology Anticorps recombines anti-gpiib/iiia
EP0990042A1 (fr) 1997-06-10 2000-04-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Sequences regulatrices impliquees dans l'expression genique regulee par l'hypoxie et leurs utilisations
NZ501990A (en) 1997-07-08 2002-09-27 Viventia Biotech Inc Compositions containing antigen-binding fragments that recognise the antigen recognised by a recombinant 4B5 antibody
JP2001514867A (ja) 1997-08-15 2001-09-18 ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ 内皮のタンパク分解活性および／または血管形成活性の刺激、調節および／または阻害
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
EP1027075A1 (fr) 1997-10-27 2000-08-16 Merck & Co., Inc. Therapie genique pour la stimulation de l'angiogenese
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
NZ511408A (en) 1998-10-09 2004-04-30 Licentia Ltd Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
CA2346798A1 (fr) 1998-10-19 2000-04-27 Ludwig Institute For Cancer Research Nouvelle liaison neuropiline/facteur de croissance et applications de celle-ci
CN1338943A (zh) 1998-10-26 2002-03-06 路德维格癌症研究院 利用vegf－c或vegf－d基因或蛋白预防再狭窄
US7223724B1 (en) * 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
EP1156820B1 (fr) 1999-02-08 2008-07-09 Human Genome Sciences, Inc. Utilisation du facteur-2 de croissance endotheliale vasculaire (vegf-2)
WO2000058511A1 (fr) 1999-03-26 2000-10-05 Ludwig Institute For Cancer Research Dosage et therapie pour les troubles lymphatiques impliquant la tyrosine kinase flt4 (vegfr-3)
US6764820B2 (en) 1999-03-26 2004-07-20 Ludwig Institute For Cancer Research Screening for lymphatic disorders involving the FLT4 receptor tyrosine kinase (VEGFR-3)
US6297238B1 (en) 1999-04-06 2001-10-02 Basf Aktiengesellschaft Therapeutic agents
WO2000061186A1 (fr) 1999-04-08 2000-10-19 Arch Development Corporation Utilisation d'anticorps anti-vegf pour accentuer le rayonnement lors d'une therapie anticancereuse
AU782819B2 (en) 1999-04-15 2005-09-01 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Angiogenic growth factors for treatment of peripheral neuropathy
CA2370404A1 (fr) 1999-04-26 2000-11-02 Serge Adnot Utilisation d'adenovirus recombinant defectif comprenant un acide nucleique codant pour un facteur angiogenique pour le traitement de l'hypertension arterielle pulmonaire
US6468543B1 (en) 1999-05-03 2002-10-22 Zymogenetics, Inc. Methods for promoting growth of bone using ZVEGF4
AU6424300A (en) 1999-05-27 2000-12-18 Max-Delbruck-Centrum Fur Molekulare Medizin Vaccines against conformation-dependent antigens and against antigens that are not or are not only proteins or peptides
MXPA01012385A (es) 1999-06-03 2002-09-02 Human Genome Sciences Inc Proteinas angiogenicas y usos de las mismas.
CA2375617A1 (fr) 1999-06-07 2000-12-14 Edwards Lifesciences Corporation Angiogenese ciblee
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
MXPA02002898A (es) 1999-09-17 2003-10-14 Abbott Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
US6420378B1 (en) 1999-10-15 2002-07-16 Supergen, Inc. Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
DE60118186T2 (de) 2000-05-12 2006-12-28 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Verwendung von inhibitoren des plazenta wachstumsfactors für die behandlung einer pathologischen angiogenese, pathologischen arteriogenese, entzündung, tumorbildung und/oder gefässdurchlässigkeit (ödem)
AU2001263281A1 (en) 2000-05-18 2001-11-26 Genetix Pharmaceuticals, Inc. Polyethylene glycol (peg) polymers for the promotion of angiogenesis
AU2001261737A1 (en) 2000-05-18 2001-11-26 Genetix Pharmaceuticals, Inc. Methods and compositions for promoting angiogenesis using monocytes
KR20020059609A (ko) * 2000-08-04 2002-07-13 벤슨 로버트 에이치. 혈관 내피 성장 인자 ２
AU2001294633A1 (en) 2000-09-29 2002-04-15 St. Elizabeth's Medical Center Endothelial cell mitogen bioassay
AU2001296521A1 (en) 2000-10-02 2002-04-15 St. Elizabeth's Medical Center Of Boston, Inc. Use of lymphangiogenic agents to treat lymphatic disorders
AU2002224471A1 (en) 2000-11-01 2002-05-15 Aventis Pharma S.A. In vivo stimulation of angiogenic activity
US20030211988A1 (en) 2001-01-09 2003-11-13 Epstein Stephen E Enhancing lymph channel development and treatment of lymphatic obstructive disease
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
US7402312B2 (en) * 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
AU2002252631A1 (en) * 2001-04-13 2002-10-28 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US20050232921A1 (en) * 2001-04-13 2005-10-20 Rosen Craig A Vascular endothelial growth factor 2
DE60236646D1 (de) * 2001-04-13 2010-07-22 Human Genome Sciences Inc Anti-VEGF-2 Antikörper
US20040031067A1 (en) 2001-10-11 2004-02-12 Meenhard Herlyn Regulation of human skin healing

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999046364A1 (fr) * 1998-03-13 1999-09-16 Human Genome Sciences, Inc. Facteur de croissance endothelial vasculaire 2

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
Abstract of Wang et al., 2005 *
HUANG, MOL THERAPY, vol. 11, 2005, pages S220 *
KUSANO K: "Sonic hedgehock induces ateriogenesis in diabetiy vasa nervorum and restores function in diabetic neuropathy", vol. 24, 2004, pages 2102 - 2107 *
LEE Y ET AL: "Improved expression of vascular endothelial growth factor by naked DNA in mouse skeletal muscles: Implication for gene therapy of ischemic diseases", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 272, 2000, pages 230 - 235 *
Material Transfer Agreement Form of Corautus Genetics Inc. , filed by applicant *
NIKOL S ET AL: "preclinical and clinical experience in vascular gene therapy: advantages over conservative/standard therapy", JOURNAL OF INVASIVE CARDIOLOGY, vol. 13, no. 4, April 2001 (2001-04-01), pages 333 - 338 *
SCHRATZBERGER PETER ET AL: "Reversal of experimental diabetic neuropathy by VEGF gene transfer", JOURNAL OF CLINICAL INVESTIGATION, vol. 107, no. 9, May 2001 (2001-05-01), pages 1083 - 1092, XP002280467, ISSN: 0021-9738 *
See also references of WO0211769A1 *
VALE P R ET AL: "Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia", CIRCULATION, AMERICAN HEART ASSOCIATION, DALLAS, TX, US, vol. 103, no. 17, 1 May 2001 (2001-05-01), pages 2138 - 2143, XP002268641, ISSN: 0009-7322 *
VALE PETER R ET AL: "Percutaneous electromechanical mapping demonstrates efficacy of pVGI.1 (VEGF2) in an animal model of chronic myocardial ischemia", CIRCULATION, vol. 100, no. 18 SUPPL., 2 November 1999 (1999-11-02), 72nd Scientific Sessions of the American Heart Association;Atlanta, Georgia, USA; November 7-10, 1999, pages I.22, XP009030849, ISSN: 0009-7322 *
WAERNER T ET AL., ANAL BIOANAL CHEM, vol. 389, 2007, pages 2109 - 2113 *
WALTER ET AL: "Local gene transfer of phVEGF-2 plasmid by gene-eluting stents", CIRCULATIOPN, vol. 110, 2004, pages 36 - 45 *

Also Published As

Publication number Publication date
CN1416354A (zh) 2003-05-07
US7273751B2 (en) 2007-09-25
CN1211126C (zh) 2005-07-20
KR20020059609A (ko) 2002-07-13
AU8473401A (en) 2002-02-18
MXPA02003434A (es) 2002-09-02
EP1313512A1 (fr) 2003-05-28
JP2004505619A (ja) 2004-02-26
WO2002011769A1 (fr) 2002-02-14
US20030215921A1 (en) 2003-11-20
US20060057117A1 (en) 2006-03-16
NZ518077A (en) 2003-11-28
CA2386103A1 (fr) 2002-02-14

Similar Documents

Publication Publication Date Title
EP1313512A4 (fr) Facteur 2 de croissance endoth liale (vegf-2)
EP1385862A4 (fr) Facteur de croissance endoth lial vasculaire 2
EP1062319A4 (fr) Facteur de croissance endothelial vasculaire 2
AU2002256172A1 (en) Vascular endothelial growth factor 2
AU6456501A (en) A method for activating only the vascular endothelial growth factor receptor-3 and uses thereof
AU5023300A (en) Vascular endothelial growth factor variants
TW539393U (en) 089204149
SG117417A1 (en) Variants of the angiogenic factor vascular endothelial cell growth factor: vegf
EP1333853A4 (fr) Complexe du facteur de croissance
AU2001228742A1 (en) Ligand for vascular endothelial growth factor receptor
AU5439998A (en) Vascular endothelial growth factor
AU2603402A (en) Novel fibroblast growth factors
HUP0200827A2 (en) Vascular endothelial cell growth factor variants and uses thereof
IL149215A0 (en) Shelving
AU5026100A (en) Vascular endothelial growth factor dimers
AU2002313770A1 (en) Vascular endothelial growth factor 2
IL153507A0 (en) Transgenically produced platelet derived growth factor
EP1163857A4 (fr) Article pour fumeurs
EP1323736A4 (fr) Facteur de croissance chimere de cellules endotheliales vasculaires de type humain
GB2349803B (en) Improvements in shelving
AU5903600A (en) A novel vascular endothelial growth factor family member and uses thereof
GB0104243D0 (en) Floodstoppers 2
GB9828377D0 (en) Vascular endothelial growth factor-e
GB0014301D0 (en) Vascular Implant
AU9149301A (en) Growth factor complex

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020502

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20040714

17Q First examination report despatched

Effective date: 20050722

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1054513

Country of ref document: HK

18D Application deemed to be withdrawn

Effective date: 20091015